深圳市中佳生物医疗科技有限公司 深圳市中佳生物医疗科技有限公司

发展历程

发展历程

Milestones

2026

In 2026, Zhongjia Biotech received a special fund of RMB 26 million from the Shenzhen Municipal Development and Reform Commission to tackle MLD cell therapy technology, and simultaneously carried out multiple self-developed clinical studies as well as clinical research on CD73+NK cells for cognitive disorders.
The company's multi-center clinical study of CD73+NK cells (ZJ-S-0106) for the treatment of mild-to-moderate Alzheimer's disease was filed with the National Health Commission (MR-N-44-2026-000065). After completing academic and ethical review, ethics approvals were obtained from several Class A tertiary hospitals, including Shenzhen Second People's Hospital, Tongji Hospital of Wuhan and Union Hospital of Wuhan, and the multi-center clinical trial was fully launched.

2025

February: Zhongjia Biotech's NK cell serum-free culture medium completed U.S. FDA DMF filing (DMF numbers: 044283, 041367, 043401, 043469)

March: The group standard 'Preparation Specification for Human Blood-Derived Natural Killer Cell Products', drafted under the leadership of Zhongjia Biotech, was approved and released by the China Food and Drug Enterprise Quality and Safety Promotion Association

June: Zhongjia Biotech launched the IND application for a cell therapy drug - gene-edited HSC for the treatment of MLD

November: Zhongjia Biotech launched new HSC, iPSC, NSC and HFSC culture media

December: Shenzhen Postdoctoral Innovation Practice Base; Guangdong Provincial Doctoral Innovation Station

2024

Zhongjia Biotech built a new R&D and production base with a construction area of 12,000 square meters in the Guangming Yinxing Synthetic Biology Industrial Park adjacent to Sun Yat-sen University (Shenzhen). In cooperation with Shenzhen Second People's Hospital, Zhongjia launched the preclinical research project 'IIT Study on the Rehabilitation Effect of ZJ-S-0106 on Cognitive Dysfunction', with plans for multi-center registration and an Investigational New Drug (IND) application.

2023

Recognized as an Innovative Small and Medium-sized Enterprise

Recognized as a Technology-based Small and Medium-sized Enterprise

Recognized as a Synthetic Biology Enterprise

Recognized as a Specialized, Refined, Distinctive and Innovative (SRDI) Enterprise

In the same year, Zhongjia Hospital was built and officially opened

2022

The company was recognized as a National High-tech Enterprise.

2021

The company completed its angel round of financing, accelerating its development once again. SGS audited and issued the ISO 9001 quality system certificate and the ISO 13485 quality system certificate. The company also obtained Class I medical device production filing and Class II medical device business filing.

2020

Zhongjia, together with Harvard Medical School and Brigham and Women's Hospital in the United States, jointly launched the 'Clinical Research on Innovative Cell Drugs for AKI and CKD' project and obtained an Investigational New Drug (IND) clinical trial approval in the United States.

2019

Shenzhen Jiake Biotechnology Co., Ltd. separated production from R&D and, on this basis, established Shenzhen Zhongjia Biomedical Science and Technology Co., Ltd. In the same year, a new R&D and production base was built in Guangming District, Shenzhen.

2018

Jiake and Shenzhen Second People's Hospital jointly carried out the clinical trial 'BsAb-NK in the Treatment of Advanced Tumors'. Among the patients, a 96-year-old veteran with melanoma achieved complete disappearance of the tumor after treatment.

2017

The company achieved another major breakthrough in NK cell culture technology. Multiple indicators, including NK cell purity, NK cell proliferation quantity and NK cell killing activity, rose to the international forefront. Jiake jointly developed clinical treatment products and technologies with Harvard Medical School and Brigham and Women's Hospital in the United States.

2016

As a core technology creator in the industry, Jiake developed rapidly. Its core technologies were integrated into the production processes of kits, culture media and other products, quickly capturing the market. After the final benchmarking of NK cell culture technology against the Japanese technology representative, Japanese technology withdrew from the Chinese market, and the company entered a brand-new era of rapid development.

2015

Jiake established an industry-university-research cooperation model with Sun Yat-sen University and other higher education institutions, forming an R&D force of 'in-house R&D team + external think tank'. Top experts in the industry were engaged as distinguished consultants, and multiple collaborative cooperation agreements were signed.

In the same year, a culture medium production line was built.


2014

Stem cell technology research was expanded. Jiake collaborated with the University of Hong Kong on the clinical trial project 'Gene Repair of Autologous Hematopoietic Stem Cells for the Treatment of Hereditary Metachromatic Leukodystrophy'. The first patient, Runrun from Taipei, received treatment at Shenzhen Second People's Hospital, and in the same year all of Runrun's indicators returned to normal levels.


2013

A GMP laboratory was built in Bao'an District, Shenzhen, and research was launched on immune cell isolation, induction, purification and expansion technologies. Multiple technical indicators reached internationally leading standards, and the technologies were transformed into production that year, capturing a substantial market share.


2012

Shenzhen Jiake Biotechnology Co., Ltd. was founded. In the same year, the company partnered with the Shenzhen Graduate School of Tsinghua University to carry out research on hair follicle stem cell technology and related fields.